Latest news
Recon: Lilly to broaden expanded access for unapproved obesity drug; Jazz to withdraw second-line SCLC indication for Zepzelca - RAPSRAPS · Tue, 04 Aug 2026 20:19:00 GMTPathos AI Licenses Alphamab's TROP2/HER3 Bispecific ADC, JSKN016 - BioPharm InternationalBioPharm International · Tue, 04 Aug 2026 17:01:14 GMTPathos AI inks deals with AstraZeneca and Alphamab - The Pharma LetterThe Pharma Letter · Tue, 04 Aug 2026 14:40:35 GMTPathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab - BioSpaceBioSpace · Tue, 04 Aug 2026 12:15:52 GMTJapan’s economy minister says pass-through of costs limited so far - SRN NewsSRN News · Tue, 04 Aug 2026 03:30:29 GMTMalaysian ruling bloc party to review role in government on Aug 16 - SRN NewsSRN News · Tue, 04 Aug 2026 03:30:26 GMTPathos AI to license experimental breast cancer drug from China's Jiangsu Alphamab Biopharmaceutical - ReutersReuters · Tue, 04 Aug 2026 02:42:29 GMTPathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC - businesswire.combusinesswire.com · Tue, 04 Aug 2026 00:00:00 GMT